Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Issue Date:

ARF No: CBE/ARF/000 30

PART A: To be completed by the	Receive	er (a separate	e form must be	completed for e	each sample	type)		
A1. Details of Sample/Specimen)							
Type/ID: (eg primary cell, cell line, tissufluid, excreta, biological agent)	ie, body	Haematopo	ietic Cell based 1	Therapies	erapies			
Format / Quantity: (eg vials, slides, e	etc)	2x50mL tube containing 24mL ficol unit						
Tissue site/Organ source:		Cord Blood	□N/A					
Batch N°:							a	
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)? If No, go to section A2.							⊠Yes □No	
Is the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?							⊠Yes □No	
Is the material obtained for storage and use under a project specific NHS REC approval?							□Yes □No	
Is the material licensable under the HTA? Indicate source below:							⊠Yes □No	
	Commer	cial Supplier	☐ Imported (fro	om outside Eng	land, Wales	or N.Ireland)	¥ 21	
ALCOHOLOGICA COMPANION CONTRACTOR OF THE STATE OF THE STA			DL 78 x2 0908201801-02			Procuro):		
If Yes, provide Project Ref N°:		BRA060 & BRA010					ê	
If Yes, provide the name of the P	Dr Rob Thomas							
A2. Details of Receipt			1					
Date/Time of receipt		Date	09/08/2018		Time:	15:00		
ID of Receiver		Name:	Jon Harriman		Dept:	CBE		
ID of Supplier/Provider		Name:	Anthony Nolan		Country:	UK		
PART B: To be completed by the	Receive	er						
B1. Inspection and Quarantine								
Has a biological risk assessment for the use of t material been approved?		ise of this	⊠Yes □No	Ref Number: BRA060 & BRA010				
Physical integrity of the material(s) accept		otable?	.⊠Yes □No	If No, describe action taken				
Quantity received correct?			⊠Yes □No	If No, describe action taken				
Labelling correct and legible?			⊠Yes □No	If No, describe action taken				
is the relevant documentation		A or equivalent evidence of		⊠Yes □No □N/A				
attached to this form?	Agree		ble transfer of	⊠Yes □No [□N/A		e .	
If No, add reference or details to ensure traceability	Details/evidence/assurance of consent			⊠Yes □No □N/A				

	Other (describe) □Yes □No □N/A								
	Building/Room		CBE H19 Cold store & once processed will be stored in - 80 overnight and transferred to Liquid N2 - Bank 7 Rack 5 Box A P04						
Temporary storage - Quarantine location (as applicable)	Storage Unit ID								
	Within storage unit location ID 4Fri-HTA & Cryo-HTA								
	within storage	unit location ib							
	Date/Time of qu	uarantine	10/07/2018 11:00						
Submitted by:	Signature:		Date: 10/07/2018						
4444									
PART C: To be completed by the departmental Quality Manager									
C1. Quality Assurance Checks									
Has the sample/specimen been s	☐Yés □No □N/A								
Has the donor been screened for	☐Yes □No □N/A								
Has the sample/specimen been s	□Yes □No □N/A								
Is there evidence that the supplie or other recognised certification	or international standards	∀Yes □No □N/A							
For HTA licensable material, is the and use of the material under the	□Yes □No □N/A								
Is there sufficient evidence to su	□Yes ☑No □N/A								
C2. Approval for release from qu	ıarantine								
Can the material be released from quarantine and transferred to designated storage area or released for processing?									
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Accept as is, bu	ut with extra controls	* *					
		Rework or repr	rocess to meet the ments						
		☐Test to meet sp	pecified requirements	,					
		☐ Return to supp	lier/provider						
		□Disposal		,					
		Building/Room							
		Storage Unit ID							
If Yes, provide details of storage applicable)	location (as	Within storage u							
		Database Referen	nce :	BT RS DXA4					
100		Date/Time of transfer							
Approved by:		Signature:	\mathcal{A}	Date:					